APPLICATIONS
Cardiovascular disease remains the leading cause of mortality both in the United States and globally. Despite the availability of conventional pharmaceutical treatments that can slow the progression of cardiac disease, there is currently a significant gap in approved therapies capable of fundamentally restoring damaged heart tissue to a healthier, pre-injury state. This unmet medical need has sparked widespread interest in the scientific and commercial sectors, driving the development of innovative regenerative therapies. These cutting-edge approaches aim to reconstruct the natural building blocks of the damaged heart, primarily focusing on stem cell and biomaterial technologies.
At the forefront of this groundbreaking innovation is Cellular Logistics’ CFX biomaterial. This advanced technology represents a promising step forward in the field of cardiac regeneration, offering the potential for more effective treatments that go beyond merely slowing disease progression to restoring heart function. The development of such regenerative therapies holds immense promise for improving patient outcomes and quality of life for those affected by cardiovascular disease. As research in this area continues to advance, it may revolutionize the approach to treating heart damage, potentially reducing the global burden of cardiovascular disease and its associated mortality rates.
CFX represents a groundbreaking approach to treating heart damage, offering dual therapeutic strategies for both acute and chronic cardiac conditions. This innovative treatment is being developed to address heart-related issues in two distinct applications:
CFX™ Solus: Acute Intervention
CFX™ Solus is designed as a standalone therapy for immediate post-heart attack care. When administered shortly after a myocardial infarction, it aims to:
- Prevent the progression of heart damage
- Reduce the risk of developing heart failure
- Potentially improve long-term cardiac outcomes
By intervening early, CFX™ Solus seeks to mitigate the cascading effects of a heart attack on cardiac tissue, potentially preserving heart function and reducing the likelihood of future complications.
CFX™ Solus Stimulates Improved Function
CFX™ Tandem: Chronic Heart Failure Treatment
For patients with chronic heart failure, CFX™ Tandem offers a combination therapy approach. This application pairs CFX with stem cells to:
- Enhance stem cell retention in the heart
- Prolong the therapeutic presence of stem cells
- Improve the efficacy of stem cell-based repair of scarred cardiac tissue
The synergistic effect of CFX™ and stem cells in the Tandem approach aims to provide a more potent and sustained treatment for patients with established heart failure.
Learn How CFX™ Tandem Enables Cell Therapies
Other Disease Applications
While CFX™ offers several commercial opportunities, including its use in delivering therapeutic cells, cell-based derivatives such as exosomes, and small molecule drugs for the treatment of ischemic heart disease, peripheral artery disease, orthopedic injury, skin injury and potentially other acute and chronic illnesses.
Our focus is to deliver a highly effective and safe product to early and late-stage regenerative medicine companies who are similarly interested in producing and marketing therapeutic solutions to fundamentally address the cardiovascular disease epidemic.